MarketCap
Facebook
X
Telegram
Mersana Therapeutics ROA Ratio | MRSN
Annual ROA Ratio Mersana Therapeutics
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -47.83 | -75.94 | -61.08 | -82.51 | -32.2 | -26.23 | -81.85 | -29.61 | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -26.23 | -82.51 | -54.66 |
Quarterly ROA Ratio Mersana Therapeutics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -69.0 | -70.51 | -57.62 | -36.18 | -53.64 | -65.82 | -52.27 | -52.27 | -71.26 | -76.11 | -76.95 | -57.99 | -78.89 | -76.02 | -69.32 | -51.02 | -61.57 | -48.9 | -43.32 | -39.88 | -44.43 | -51.31 | -55.87 | -60.43 | -73.89 | -87.36 | -100.83 | -114.3 | -96.41 | -97.45 | -98.48 | -99.52 | -87.64 | -71.06 | -54.49 | 1.2 | -13.04 | -13.04 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.2 | -114.3 | -63.86 |
ROA Ratio of other stocks in the Biotechnology industry
| Issuer | ROA Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Spero Therapeutics
SPRO
|
12.44 | $ 1.02 | 1.49 % | $ 57.1 M |  USA |
 |
Praxis Precision Medicines
PRAX
|
-32.31 | $ 346.47 | 2.63 % | $ 7.8 B | USA |
 |
Prelude Therapeutics Incorporated
PRLD
|
-70.41 | $ 3.8 | 1.06 % | $ 292 M | USA |
 |
ProQR Therapeutics N.V.
PRQR
|
-37.41 | $ 1.26 | -3.82 % | $ 133 M |  Niderland |
 |
Ocular Therapeutix
OCUL
|
-32.91 | $ 6.66 | 0.68 % | $ 1.25 B | USA |
 |
PolyPid Ltd.
PYPD
|
-153.18 | $ 6.56 | 3.96 % | $ 107 M |  Israel |
 |
Outlook Therapeutics
OTLK
|
-335.9 | $ 0.48 | 4.34 % | $ 16.7 M | USA |
 |
uniQure N.V.
QURE
|
-24.12 | $ 24.64 | 8.5 % | $ 1.42 B | Niderland |
 |
Ultragenyx Pharmaceutical
RARE
|
-37.53 | $ 16.7 | 3.44 % | $ 1.65 B | USA |
 |
Sarepta Therapeutics
SRPT
|
-21.3 | $ 16.67 | 1.4 % | $ 1.67 B | USA |
 |
Rafael Holdings
RFL
|
-35.68 | $ 1.12 | 4.67 % | $ 57.6 M | USA |
 |
REGENXBIO
RGNX
|
-42.8 | $ 8.57 | 11.38 % | $ 442 M | USA |
 |
Rigel Pharmaceuticals
RIGL
|
71.46 | $ 44.17 | 0.58 % | $ 794 M | USA |
 |
SELLAS Life Sciences Group
SLS
|
-34.29 | $ 8.41 | 0.5 % | $ 917 M | USA |
 |
Celsion Corporation
CLSN
|
117.96 | - | -6.63 % | $ 13.9 M | USA |
 |
I-Mab
IMAB
|
-56.09 | - | - | $ 866 M |  China |
 |
Tenax Therapeutics
TENX
|
-50.47 | $ 1.7 | 0.3 % | $ 66.7 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
3.33 | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
1.0 | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
-142.36 | - | -13.47 % | $ 169 M | France |
 |
CureVac N.V.
CVAC
|
20.2 | - | - | $ 867 M |  Germany |
 |
BiondVax Pharmaceuticals Ltd.
BVXV
|
-40.14 | - | 0.74 % | $ 768 M | Israel |
 |
Abcam plc
ABCM
|
-0.8 | - | - | $ 4.9 B |  Britain |
 |
Rezolute
RZLT
|
-68.75 | $ 4.09 | 1.74 % | $ 425 M | USA |
 |
Midatech Pharma plc
MTP
|
-35.12 | - | -18.52 % | $ 27.3 M | Britain |
 |
Tiziana Life Sciences PLC
TLSA
|
-105.13 | $ 0.62 | 1.33 % | $ 66.1 M | Britain |
 |
MorphoSys AG
MOR
|
-9.36 | - | 2.43 % | $ 254 M | Germany |
 |
Affimed N.V.
AFMD
|
-109.04 | - | -34.95 % | $ 21.5 M | Germany |
 |
AnPac Bio-Medical Science Co., Ltd.
ANPC
|
-251.78 | - | -1.58 % | $ 28.1 M | China |
 |
Celyad Oncology SA
CYAD
|
-207.62 | - | - | $ 12.5 M |  Belgium |
 |
Seer
SEER
|
-24.86 | $ 1.61 | -0.31 % | $ 88.9 M | USA |
 |
Gracell Biotechnologies
GRCL
|
-36.68 | - | - | $ 3.37 B | China |
 |
Shattuck Labs
STTK
|
-53.62 | $ 5.04 | 3.61 % | $ 351 M | USA |
|
Silence Therapeutics plc
SLN
|
-25.66 | $ 19.78 | -0.05 % | $ 2.8 B | Britain |
 |
Stoke Therapeutics
STOK
|
-1.65 | $ 27.75 | 1.98 % | $ 1.64 B | USA |
 |
Sutro Biopharma
STRO
|
-109.88 | $ 10.25 | 0.79 % | $ 87.1 M | USA |
 |
Soligenix
SNGX
|
-120.19 | $ 0.32 | 0.37 % | $ 1.66 M | USA |
 |
Teva Pharmaceutical Industries Limited
TEVA
|
3.46 | $ 43.19 | 1.85 % | $ 49.5 B | Israel |
 |
China SXT Pharmaceuticals
SXTC
|
-17.85 | $ 2.96 | 2.78 % | $ 2.01 M | China |
 |
Spruce Biosciences
SPRB
|
-73.49 | $ 46.52 | -0.32 % | $ 35.7 M | USA |
 |
Takeda Pharmaceutical Company Limited
TAK
|
0.76 | $ 20.83 | -0.38 % | $ 32.9 B |  Japan |
 |
Supernus Pharmaceuticals
SUPN
|
-2.66 | $ 29.29 | 1.88 % | $ 1.65 B | USA |
 |
Galapagos NV
GLPG
|
9.42 | - | - | $ 1.83 B | Belgium |
 |
Savara
SVRA
|
-46.89 | $ 5.03 | 2.24 % | $ 1.12 B | USA |
 |
Teligent, Inc.
TLGT
|
-12.14 | - | -13.85 % | $ 16.1 M | USA |
 |
Viela Bio, Inc.
VIE
|
-35.6 | - | - | $ 2.91 B | USA |
 |
TG Therapeutics
TGTX
|
42.06 | $ 65.76 | 2.33 % | $ 9.49 B | USA |
 |
Aphria Inc.
APHA
|
-3.39 | - | -0.45 % | $ 4.87 B |  Canada |
 |
Aerpio Pharmaceuticals, Inc.
ARPO
|
-9.61 | - | -0.90 % | $ 104 M | USA |